Printer friendly version Share

News Release

MAYO-CLINIC-LOGO_copy_copy_copy_copy

Please register to view contact details

Four-Drug Mix Treats Multiple Myeloma With Fewer Side Effects Mayo Clinic-Led Study Finds

05 June 2012 Mayo Clinic

SCOTTSDALE, Ariz. -- A four-drug combination of chemotherapy drugs scored high marks as a highly effective treatment for patients newly diagnosed with the blood cancer multiple myeloma, according to results from a Mayo Clinic-led study. The multidrug regimen, called CYCLONE (comprised of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone), boasted strong results in the phase II trial, most notably for how quickly and effectively it worked and how well tolerated it was by the study recipients.

"Within only four cycles of treatment, 96 percent of patients responded favorably to the therapy," says lead researcher Joseph Mikhael, M.D., a hematologist at Mayo Clinic in Arizona. "Furthermore, 75 percent experienced a very good partial remission — meaning there was a 90 percent reduction of their tumor. A third of the patients experienced a complete remission, where the tumor was no longer detectable."

Dr. Mikhael is presenting the study at an American Society of Clinical Oncology conference in Chicago. 

The study participants also experienced fewer side effects compared to currently available therapies, Dr. Mikhael adds. Side effects associated with multiple myeloma treatment typically involve the nerves of the body, and include numbness, tingling and pain. The American Cancer Society projects 21,700 new cases of multiple myeloma will be diagnosed this year. Multiple myeloma is an incurable cancer of the plasma cells, found within the bone marrow. Abnormal plasma cells (myeloma cells) multiply in the bone marrow, resulting in fewer healthy blood cells. These abnormal plasma cells also produce an abnormal protein known as a monoclonal, or M protein, that can cause bone fractures and damage organs, especially the kidneys.

Patients are typically treated with chemotherapy followed by a stem cell transplant.

Dr. Mikhael says the next step of the trial is to increase the dosage of Carfilzomib to attempt an even deeper response with limited side effects. 

 

http://www.mayoclinic.org/news2012-sct/6915.html